-
Mashup Score: 1
A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Ponatinib demonstrated long-term efficacy in patients with T315I-mutated chronic-phase CML, according to data from the phase 2 OPTIC trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Blinatumomab consolidation increases the likelihood of achieving MRD negativity when compared to chemotherapy consolidation in AYAs with ALL.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL - 3 month(s) ago
Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL - 3 month(s) ago
Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL - 4 month(s) ago
The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL - 4 month(s) ago
The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL @eha_hematology #EHA2024 #leusm https://t.co/KWUDEtf7Cd